Literature DB >> 15063402

Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin.

Carl Atkinson1, Joanne Horsley, Susan Rhind-Tutt, Susan Charman, Colin J Phillpotts, John Wallwork, Martin J Goddard.   

Abstract

BACKGROUND: Transplant coronary artery vasculopathy (CAV) is a fibro-proliferative process that leads to lumen occlusion and cardiac failure. Current theories suggest that the process evolves over time in response to inflammation and proliferation of donor derived medial smooth muscle cells (SMC). Animal models of cardiac transplantation have suggested that the neointima is formed by recipient derived circulating progenitor cells. The aim of this investigation is to determine the origin of the neointimal SMC within epicardial coronary arteries from human cardiac allografts by using sex mis-matched recipients and donors, and a Y specific chromosome probe.
METHODS: Coronary arteries from 14 patients previously assessed histologically to have CAV were analyzed-eight male recipients of female donor organs, 2 female-to-female, and 4 male-to-male transplants. A double immunocytochemistry and in-situ hybridization technique using a Y chromosome DNA probe and either antibodies to smooth muscle actin or Ham-56 a macrophage marker were employed.
RESULTS: No Y chromosome bodies could be identified in the female-to-female allografts. In the 4 male donor and male recipient cases, cells positive for the Y chromosome probe were identified. In sex mis-matched transplants, female to male, inflammatory cells marked with Ham-56 were also positive for Y chromosome probe. Flattened cells positive for Y chromosome were observed just beneath the endothelial surface. When double stained, these were identified as infiltrating macrophages. No double staining smooth muscle cells and Y chromosome positive cells could be identified within the neointima.
CONCLUSIONS: This study confirms the source of SMC of the neointima of CAV lesions from epicardial coronary arteries to be of donor origin. In contrast to animal models, circulating progenitor cells do not appear to play a role within the neointima of human transplant CAV.

Entities:  

Mesh:

Year:  2004        PMID: 15063402     DOI: 10.1016/S1053-2498(03)00222-5

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  14 in total

1.  Cardiac allograft vasculopathy: real or a normal morphologic variant?

Authors:  Stuart Houser; Ashok Muniappan; James Allan; David Sachs; Joren Madsen
Journal:  J Heart Lung Transplant       Date:  2007-02       Impact factor: 10.247

Review 2.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

3.  Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells.

Authors:  Zuzana Tobiasova; Lufeng Zhang; Tai Yi; Linfeng Qin; Thomas D Manes; Sanjay Kulkarni; Marc I Lorber; Frederick C Rodriguez; Je-Min Choi; George Tellides; Jordan S Pober; Ivana Kawikova; Alfred L M Bothwell
Journal:  Circulation       Date:  2011-06-20       Impact factor: 29.690

4.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

5.  Characteristics of cardiac allograft vasculopathy induced by immunomodulation in the miniature Swine.

Authors:  Jun Amano; Tomohiro Akashima; Takamitsu Terasaki; Yuko Wada; Midori Ito-Amano; Jun-Ichi Suzuki; Mitsuaki Isobe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2014-04-18       Impact factor: 1.520

Review 6.  Chemokines and transplant vasculopathy.

Authors:  John A Belperio; Abbas Ardehali
Journal:  Circ Res       Date:  2008-08-29       Impact factor: 17.367

Review 7.  Endothelial dysfunction and cardiac allograft vasculopathy.

Authors:  Monica Colvin-Adams; Nonyelum Harcourt; Daniel Duprez
Journal:  J Cardiovasc Transl Res       Date:  2012-11-08       Impact factor: 4.132

Review 8.  Progenitor cells and vascular disease.

Authors:  M Jevon; A Dorling; P I Hornick
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

9.  Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.

Authors:  Feng-Yen Lin; Chun-Min Shih; Chun-Yao Huang; Yi-Tin Tsai; Shih-Hurng Loh; Chi-Yuan Li; Cheng-Yen Lin; Yi-Wen Lin; Chien-Sung Tsai
Journal:  Cardiovasc Drugs Ther       Date:  2021-12       Impact factor: 3.727

Review 10.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.